CSL employees.
William West | AFP | Getty Images
Shares of Australian biotech firm CSL plunged 17% Wednesday after it announced that Chief Executive Officer Paul McKenzie will step down with immediate effect, and posted weak earnings for the first half of the year.
Former senior executive Gordon Naylor will serve as interim CEO until a permanent replacement is found.
This is breaking news. Please check back for updates.
